Juliana

[Khandan Keyomarsi @kandymarsy]

Happy to share our SPOTLIGHT piece in @AACR describing distinct mechanisms of resistance to the different CDK4/6 inhibitors. As such, patients who progress on each of the CDK4/6 inhibitors may respond to different types of subsequent therapies. https://t.co/Slo5VaeLTS

[Khandan Keyomarsi @kandymarsy]

Our novel finding on distinct mechanisms of resistance to palbociclib and abemaciclib in HR+ / HER2- MBC. Is there rationale for switching CDK4/6i after progression? @kandymarsy @KellyKhunt @MDAndersonNews @CR_AACR @HarmonyTurk https://t.co/BMmXIlJ3kt

[Khandan Keyomarsi @kandymarsy]

KeyHunt lab enjoying dinner @aacr22 with @SofiaMast1 and @KellyKhunt and @junay_14 and @ndttuyen and Hannah Wingate and Kara Lewis

[Nicole M. Kettner, PhD @kettnernm]

Excited to be at #AACR22 with first-timers @junay_14 and @ndttuyen

[Juliana @junay_14]

Making sure our research continues going on even with extreme conditions

[Juliana @junay_14]

We are back! 👩‍🔬👨‍🔬 AM shift KeyHunt-lab

[Kelly K Hunt @KellyKhunt]

Having a grand time with the ⁦@MDAndersonNews⁩ KeyHunt gang at #SABCS2019 ⁦@kandymarsy⁩ ⁦@KellyKhunt⁩ #endcancer

[Komal S. Rasaputra, PhD @KomalRasaputra]

Outstanding presentations by #KeyHunt lab @SABCS2019 focusing on early and metastatic ER -positive breast cancer translational research! Kudos to the team science! @KellyKhunt @kandymarsy @DrDebuTripathy @SofiaMast1 @AmritiLulla @junay_14 @MDAndersonNews NicoleKettner, Mi Li